Search research articles
Contact Us
Filters
Showing results (531-540 of 649) with videos related to
Page
of 65
Sort By:
Breast Cancer Research and Treatment
|
June 22, 2014
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Jacek Gronwald, Andre Robidoux, Charmaine Kim-Sing, et al.
Lancet (London, England)
|
June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2019
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Ingrid A Mayer, Aleix Prat, Daniel Egle, et al.
British Journal of Cancer
|
March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors
Martin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
Breast Cancer Research and Treatment
|
October 15, 2014
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers
Xinglei Chai, Tara M Friebel, Christian F Singer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 28, 2026
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in <i>BRCA1</i> or <i>BRCA2</i>
Adriana I Apostol, Jacek Gronwald, Cezary Cybulski, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)
Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
Journal of the National Cancer Institute
|
December 17, 2025
Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2
Joanne Kotsopoulos, Marta Seca, Jacek Gronwald, et al.
Breast Cancer Research : BCR
|
October 22, 2009
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
Susan L Neuhausen, Sean Brummel, Yuan Chun Ding, et al.
Page
of 65
Search research articles
Search
Showing results (531-540 of 649) with videos related to
Sort By:
Page
of 65
Breast Cancer Research and Treatment
|
June 22, 2014
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Jacek Gronwald, Andre Robidoux, Charmaine Kim-Sing, et al.
Lancet (London, England)
|
June 5, 2015
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant, Georg Pfeiler, Peter C Dubsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2019
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Ingrid A Mayer, Aleix Prat, Daniel Egle, et al.
British Journal of Cancer
|
March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors
Martin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
Breast Cancer Research and Treatment
|
October 15, 2014
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers
Xinglei Chai, Tara M Friebel, Christian F Singer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 28, 2026
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in <i>BRCA1</i> or <i>BRCA2</i>
Adriana I Apostol, Jacek Gronwald, Cezary Cybulski, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)
Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
Journal of the National Cancer Institute
|
December 17, 2025
Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2
Joanne Kotsopoulos, Marta Seca, Jacek Gronwald, et al.
Breast Cancer Research : BCR
|
October 22, 2009
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers
Susan L Neuhausen, Sean Brummel, Yuan Chun Ding, et al.
Page
of 65